METHODS FOR TREATING INFECTIONS

1 . A method for treating or reducing the risk of a microbial infection in a patient in need thereof comprising:

(a) intravenously administering an intravenous formulation comprising a pharmaceutically effective amount of a quinolone carboxylic acid derivative or a pharmaceutically acceptable salt or ester thereof according to a schedule of once daily or twice daily from about 1 to about 7 days consecutively; and thereafter

(b) orally administering an oral formulation comprising a pharmaceutically effective amount of said quinolone carboxylic acid derivative or said pharmaceutically acceptable salt or ester thereof according to a schedule of once daily or twice daily from about 1 to about 14 days consecutively;

wherein said quinolone carboxylic acid derivative corresponds to the following compound (A)

or a pharmaceutically acceptable salt or ester thereof.

2 . The method of claim 1 , wherein

(a) said intravenous administration is from about 1 to about 4 days consecutively; and

(b) said oral administration is from about 1 to about 7 days consecutively.

3 . The method of claim 1 , wherein said intravenous administration is from about 1 to about 3 days consecutively.

4 . The method of claim 1 , wherein said oral administration is from about 2 to about 11 days consecutively.

5 . The method of claim 1 , wherein said oral administration is from about 1 to about 4 days consecutively.

6 . The method of claim 1 , wherein said oral administration is twice daily.

7 . The method of claim 1 , wherein said pharmaceutically acceptable salt of said quinolone carboxylic acid derivative is a D-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylate.

8 . The method of claim 1 , wherein said pharmaceutically acceptable salt of said quinolone carboxylic acid derivative is a crystalline D-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylate characterized by an X-ray powder diffraction pattern substantially in accordance with that shown in FIG. 1 , wherein the pattern is obtained from a copper radiation source (Cu—Kα 40 kV, 4 mA).

9 . The method of claim 1 , wherein the pharmaceutically acceptable salt of said quinolone carboxylic acid derivative is a crystalline D-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylate characterized by an X-ray powder diffraction pattern having peaks at about 6.35, 12.70, 19.10 and 20.50 degrees 2θ, wherein the pattern is obtained from a copper radiation source (Cu—Kα, 40 kV, 4 mA).

10 . The method of claim 8 , wherein the crystalline form is characterized by a melting point of about 168-171° C.

11 . The method of claim 8 , wherein the crystalline form is characterized by the differential scanning calorimetry thermogram shown in FIG. 3 .

12 . The method of claim 1 , wherein said pharmaceutically acceptable salt of said quinolone carboxylic acid derivative is D-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylate trihydrate.

13 . The method of claim 1 , wherein said pharmaceutically acceptable salt of said quinolone carboxylic acid derivative is crystalline D-glucitol, 1-deoxy-1-(methylamino)-, 1-(6-amino-3,5-difluoro-2-pyridinyl)-8-chloro-6-fluoro-1,4-dihydro-7-(3-hydroxy-1-azetidinyl)-4-oxo-3-quinolinecarboxylate trihydrate, characterized, when measured at about 25° C. with Cu—Kα radiation, by the X-ray powder diffraction pattern shown in FIG. 2 .

14 . The method of claim 1 , wherein the intravenous formulation comprises from about 100 mg to about 750 mg of said quinolone carboxylic acid derivative on an acid active basis, wherein said quinolone carboxylic acid derivative is delafloxacin or a pharmaceutically acceptable salt thereof.

15 . The method of claim 14 , wherein the intravenous formulation comprises about 300 mg of delafloxacin or a pharmaceutically acceptable salt thereof, on an acid active basis.

16 . The method of claim 1 , wherein the oral formulation comprises from about 100 mg to about 750 mg of said quinolone carboxylic acid derivative, on an acid active basis, wherein said quinolone carboxylic acid derivative is delafloxacin or a pharmaceutically acceptable salt thereof.

17 . The method of claim 16 , wherein the oral formulation comprises about 400 mg of delafloxacin or a pharmaceutically acceptable salt thereof, on an acid active basis.

18 . The method of claim 16 , wherein the oral formulation comprises about 450 mg of delafloxacin or a pharmaceutically acceptable salt thereof, on an acid active basis.

19 . The method of claim 1 , wherein the oral formulation is in the form of a tablet or a capsule.

20 . The method of claim 19 , wherein the oral formulation is in the form of a tablet and said tablet comprises:

(a) about 450 mg of said quinolone carboxylic acid derivative, wherein said quinolone carboxylic acid derivative is delafloxacin or a pharmaceutically acceptable salt thereof; and

(b) about 150 mg of an effervescent agent comprising a mixture of sodium bicarbonate, sodium dihydrogen phosphate, and citric acid.

21 . The method of claim 19 , wherein the oral formulation is in the form of a tablet and said tablet comprises:

(a) about 650 mg of said quinolone carboxylic acid derivative, wherein said quinolone carboxylic acid derivative is delafloxacin meglumine; and

(b) about 150 mg of an effervescent agent comprising a mixture of sodium bicarbonate, sodium dihydrogen phosphate, and citric acid.

22 . The method of claim 1 , wherein said intravenous administration is from about 1 to about 3 days consecutively and said oral administration is from about 1 to about 4 days consecutively.

23 . The method of claim 1 , wherein said intravenous administration is from about 1 to about 3 days consecutively and said oral administration is from about 2 to about 11 days consecutively.

24 . The method of claim 22 , wherein said intravenous formulation comprises about 300 mg of delafloxacin or a pharmaceutically acceptable salt thereof.

25 . The method of claim 22 , wherein said oral formulation comprises about 400 mg of delafloxacin or a pharmaceutically acceptable salt thereof.

26 . The method of claim 22 , wherein said oral formulation comprises about 450 mg of delafloxacin or a pharmaceutically acceptable salt thereof.

27 . The method of claim 24 , wherein said oral formulation comprises about 400 mg of delafloxacin or a pharmaceutically acceptable salt thereof.

28 . The method of claim 24 , wherein said oral formulation comprises about 450 mg of delafloxacin or a pharmaceutically acceptable salt thereof.

29 . The method of claim 23 , wherein said intravenous formulation comprises about 300 mg of delafloxacin or a pharmaceutically acceptable salt thereof.

30 . The method of claim 23 , wherein said oral formulation comprises about 400 mg of delafloxacin or a pharmaceutically acceptable salt thereof.

31 . The method of claim 23 , wherein said oral formulation comprises about 450 mg of delafloxacin or a pharmaceutically acceptable salt thereof.

32 . The method of claim 29 , wherein said oral formulation comprises about 400 mg of delafloxacin or a pharmaceutically acceptable salt thereof.

33 . The method of claim 29 , wherein said oral formulation comprises about 450 mg of delafloxacin or a pharmaceutically acceptable salt thereof.

34 . The method of claim 1 , wherein said intravenous administration is twice daily.

35 . The method of claim 1 , wherein the microbial infection is community acquired pneumonia.

36 . The method of claim 1 , wherein the microbial infection is an acute bacterial skin and skin structure infection.